Sitagliptin: Uses, Dosage & Side Effects
DPP-4 inhibitor for type 2 diabetes mellitus
Quick Facts About Sitagliptin
Key Takeaways About Sitagliptin
- Effective blood sugar control: Sitagliptin reduces HbA1c by approximately 0.5–0.8% as monotherapy, with additional benefit when combined with metformin
- Low risk of hypoglycemia: When used alone or with metformin, sitagliptin has a low risk of causing dangerously low blood sugar
- Once-daily dosing: The standard dose is 100 mg once daily, taken with or without food, making it convenient for patients
- Dose adjustment for kidneys: Patients with reduced kidney function require lower doses (50 mg or 25 mg) – your doctor will assess this
- Proven cardiovascular safety: The TECOS trial demonstrated that sitagliptin does not increase the risk of major cardiovascular events in patients with type 2 diabetes
What Is Sitagliptin and What Is It Used For?
Sitagliptin is a DPP-4 inhibitor (dipeptidyl peptidase-4 inhibitor) that lowers blood sugar in adults with type 2 diabetes. It works by boosting incretin hormones, which stimulate insulin release after eating and reduce the liver's glucose production. It is taken once daily as a tablet and can be used alone or with other diabetes medications.
Sitagliptin belongs to a group of medications called DPP-4 inhibitors, also known as gliptins. These drugs work by inhibiting the enzyme dipeptidyl peptidase-4, which normally breaks down incretin hormones in the body. The two key incretin hormones are GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide). By preventing their breakdown, sitagliptin allows these hormones to remain active for longer, leading to increased insulin secretion after meals and decreased glucagon release – both of which help lower blood sugar levels.
A key advantage of sitagliptin's mechanism of action is that it works in a glucose-dependent manner. This means the drug primarily stimulates insulin release when blood sugar is elevated (such as after eating) and reduces its effect when blood sugar is normal or low. This characteristic contributes to the relatively low risk of hypoglycemia (low blood sugar) associated with sitagliptin when used as monotherapy or in combination with metformin.
Your doctor may prescribe sitagliptin when diet and exercise alone are not sufficient to control your blood sugar, or when other medications such as metformin alone do not provide adequate glycemic control. Sitagliptin can be prescribed as a standalone treatment or in combination with other blood-sugar-lowering medications including metformin, sulfonylureas (such as glimepiride or glipizide), thiazolidinediones (pioglitazone), or insulin.
What is type 2 diabetes?
Type 2 diabetes is a chronic metabolic condition in which your body either does not produce enough insulin or cannot effectively use the insulin it produces – a phenomenon known as insulin resistance. Insulin is a hormone produced by the pancreas that allows glucose (sugar) from the food you eat to enter your cells and be used for energy. When insulin function is impaired, glucose builds up in the bloodstream, leading to elevated blood sugar levels (hyperglycemia).
Over time, persistently high blood sugar can damage blood vessels and nerves throughout the body, increasing the risk of serious complications including heart disease, stroke, kidney disease (diabetic nephropathy), eye damage (diabetic retinopathy), and nerve damage (diabetic neuropathy). Effective blood sugar management through lifestyle modifications and medication significantly reduces these risks. According to the American Diabetes Association (ADA) Standards of Care 2025, maintaining an HbA1c level below 7% is a reasonable target for most adults with diabetes, although individualized targets are recommended.
Unlike sulfonylureas or insulin, which directly stimulate insulin secretion regardless of blood sugar levels, sitagliptin enhances the body's natural incretin system and works primarily when blood sugar is elevated. This means it is less likely to cause hypoglycemia. Sitagliptin is also weight-neutral, meaning it generally does not cause significant weight gain or weight loss – an advantage over some other diabetes treatments.
What Should You Know Before Taking Sitagliptin?
Do not take sitagliptin if you are allergic to sitagliptin or any of its ingredients. Tell your doctor about any history of pancreatitis, kidney problems, or gallstones before starting treatment. Sitagliptin should not be used during pregnancy or breastfeeding.
Before starting treatment with sitagliptin, it is essential that your healthcare provider has a complete picture of your medical history and current medications. This information helps ensure that sitagliptin is safe and appropriate for you. Open communication with your doctor is crucial for safe and effective diabetes management.
Contraindications
You should not use sitagliptin if you have a known allergy (hypersensitivity) to sitagliptin or any of the other ingredients in the tablets. Serious allergic reactions, including anaphylaxis, angioedema (swelling beneath the skin), and exfoliative skin conditions such as Stevens-Johnson syndrome, have been reported in post-marketing surveillance. If you have previously experienced any allergic reaction to sitagliptin, you must not take it again.
Sitagliptin is not appropriate for the treatment of type 1 diabetes or diabetic ketoacidosis (DKA). Type 1 diabetes requires insulin therapy, and sitagliptin cannot replace insulin in these patients. If you have elevated ketone levels in your blood or urine along with high blood sugar, rapid weight loss, nausea, or vomiting, contact your healthcare provider immediately as these may be signs of diabetic ketoacidosis.
Warnings and Precautions
Inform your doctor before taking sitagliptin if you have or have had any of the following conditions:
- Pancreatitis: Cases of acute pancreatitis (inflammation of the pancreas) have been reported in patients taking sitagliptin. If you have a history of pancreatitis, your doctor will weigh the risks and benefits carefully. Risk factors for pancreatitis include gallstones, alcohol dependence, and very high triglyceride levels.
- Kidney disease: If you have reduced kidney function, your doctor may prescribe a lower dose of sitagliptin. Blood tests to monitor your kidney function may be recommended periodically during treatment.
- Bullous pemphigoid: Rare cases of bullous pemphigoid, a skin condition characterized by large, fluid-filled blisters, have been reported. If you develop blisters on your skin, stop taking sitagliptin and contact your doctor.
- Heart failure: While the TECOS cardiovascular outcomes trial showed no increased risk of heart failure hospitalization with sitagliptin, patients with a history of heart failure should be monitored.
When sitagliptin is used in combination with a sulfonylurea or insulin, the risk of hypoglycemia (low blood sugar) increases. Your doctor may reduce the dose of your sulfonylurea or insulin to minimize this risk. Signs of hypoglycemia include sweating, shakiness, rapid heartbeat, hunger, confusion, and dizziness. When used alone or with metformin only, sitagliptin is unlikely to cause hypoglycemia.
Children and Adolescents
Sitagliptin is not recommended for use in children and adolescents under 18 years of age. Clinical studies in pediatric patients aged 10 to 17 years showed that sitagliptin was not effective in lowering blood sugar levels in this age group. The safety and efficacy of sitagliptin in children under 10 years old have not been established. Other diabetes medications approved for pediatric use should be considered for younger patients.
Pregnancy and Breastfeeding
Sitagliptin should not be used during pregnancy. There is insufficient data from clinical studies in pregnant women to establish the safety of sitagliptin during pregnancy. Animal reproductive studies have shown some adverse effects at high doses. If you are pregnant, planning to become pregnant, or discover you are pregnant while taking sitagliptin, consult your healthcare provider immediately about switching to a pregnancy-safe alternative. Insulin is generally the preferred treatment for managing diabetes during pregnancy.
It is not known whether sitagliptin passes into breast milk. As a precaution, sitagliptin should not be used while breastfeeding. Discuss alternative treatment options with your healthcare provider if you are breastfeeding or planning to breastfeed.
Driving and Operating Machinery
Sitagliptin has no or negligible direct effect on the ability to drive or operate machinery. However, cases of dizziness and drowsiness have been reported, which may affect your ability to drive or use machines safely. Additionally, when sitagliptin is used in combination with sulfonylureas or insulin, hypoglycemia may occur, which can impair concentration and reaction time. Exercise caution until you know how the medication affects you.
How Does Sitagliptin Interact with Other Drugs?
Sitagliptin has relatively few clinically significant drug interactions. The most important interaction to be aware of is with digoxin, where monitoring may be required. When combined with sulfonylureas or insulin, the dose of these other medications may need to be reduced to prevent low blood sugar.
Sitagliptin is primarily eliminated by the kidneys through active tubular secretion. It is not extensively metabolized by liver enzymes (cytochrome P450) and does not significantly inhibit or induce CYP enzymes, which limits its potential for drug-drug interactions. However, there are still some important interactions to be aware of.
Always tell your doctor or pharmacist about all medications you are taking, have recently taken, or plan to take. This includes prescription drugs, over-the-counter medications, herbal supplements, and vitamins.
| Interacting Drug | Effect | Clinical Significance | Recommendation |
|---|---|---|---|
| Digoxin | Slight increase in digoxin plasma levels | Moderate | Monitor digoxin levels; dose adjustment may be needed |
| Sulfonylureas (e.g., glimepiride, glipizide) | Increased risk of hypoglycemia | Major | Reduce sulfonylurea dose when combining with sitagliptin |
| Insulin | Increased risk of hypoglycemia | Major | Reduce insulin dose when adding sitagliptin |
| Metformin | Complementary glucose-lowering; no pharmacokinetic interaction | Beneficial | Safe combination; standard doses of both drugs can be used |
| Cyclosporine | May increase sitagliptin levels via P-glycoprotein inhibition | Moderate | Monitor for increased sitagliptin effects |
Major Interactions
The most clinically important interactions occur when sitagliptin is combined with other blood-sugar-lowering medications that carry a risk of hypoglycemia on their own. Sulfonylureas (such as glimepiride, glipizide, and glyburide) and insulin both directly stimulate insulin release, and adding sitagliptin can amplify this effect. Your prescriber should consider reducing the dose of the sulfonylurea or insulin when starting sitagliptin to prevent episodes of low blood sugar.
Minor Interactions
Co-administration of sitagliptin with digoxin resulted in a small increase in the area under the curve (AUC) of digoxin by approximately 11% and peak plasma concentration (Cmax) by approximately 18%. These increases are generally not considered clinically significant for most patients, but digoxin has a narrow therapeutic index. Therefore, patients receiving both medications should be monitored appropriately, and digoxin dose adjustments may be necessary based on serum digoxin levels.
No significant pharmacokinetic interactions have been observed with commonly co-prescribed medications including metformin, rosiglitazone, glyburide, simvastatin, warfarin, or oral contraceptives. Sitagliptin can generally be combined safely with these medications without dose adjustments.
What Is the Correct Dosage of Sitagliptin?
The recommended dose of sitagliptin is 100 mg once daily for adults with normal kidney function. The dose is reduced to 50 mg for moderate kidney impairment and 25 mg for severe kidney impairment or dialysis. Take the tablet with or without food at approximately the same time each day.
Always take sitagliptin exactly as your doctor has prescribed. Do not change your dose without consulting your healthcare provider. The dosage is determined primarily by your kidney function, which your doctor will assess through blood tests.
| Patient Group | Kidney Function (eGFR) | Recommended Dose | Frequency |
|---|---|---|---|
| Adults – normal or mild impairment | eGFR ≥ 45 mL/min | 100 mg | Once daily |
| Adults – moderate impairment | eGFR 30–44 mL/min | 50 mg | Once daily |
| Adults – severe impairment / dialysis | eGFR < 30 mL/min | 25 mg | Once daily |
| Elderly (≥ 65 years) | Based on kidney function | As above per eGFR | Once daily |
| Children (< 18 years) | N/A | Not recommended | N/A |
Adults
For adults with normal kidney function or mild kidney impairment, the recommended dose of sitagliptin is 100 mg once daily. The tablet can be taken with or without food, at any time of day, though it is advisable to take it at approximately the same time each day to maintain consistent blood levels. Sitagliptin can be prescribed alone (monotherapy) or in combination with other antidiabetic medications.
When sitagliptin is added to an existing regimen that includes a sulfonylurea or insulin, your doctor may reduce the dose of the sulfonylurea or insulin to lower the risk of hypoglycemia. No dose adjustment is required when combining sitagliptin with metformin or pioglitazone.
Diet and exercise play a vital role in managing type 2 diabetes and should be continued alongside sitagliptin therapy. Your healthcare provider will likely recommend a balanced diet, regular physical activity, and periodic blood sugar monitoring to ensure optimal glycemic control.
Children
Sitagliptin is not recommended for children and adolescents under 18 years of age. A clinical trial in pediatric patients aged 10 to 17 years with type 2 diabetes did not demonstrate efficacy, as sitagliptin did not significantly reduce HbA1c compared to placebo. No data are available for children under 10 years. For pediatric patients with type 2 diabetes, metformin and insulin remain the primary pharmacological treatment options as recommended by international guidelines including the ADA and International Society for Pediatric and Adolescent Diabetes (ISPAD).
Elderly
No dose adjustment based on age alone is necessary for elderly patients (≥ 65 years). However, since kidney function naturally declines with age, elderly patients are more likely to require a reduced dose based on their estimated glomerular filtration rate (eGFR). Your doctor will assess your kidney function before prescribing sitagliptin and may perform periodic monitoring. In clinical trials, sitagliptin was generally well tolerated in older adults, with a safety profile comparable to that seen in younger patients.
Missed Dose
If you forget to take a dose of sitagliptin, take it as soon as you remember. However, if it is almost time for your next scheduled dose, skip the missed dose and continue with your regular dosing schedule. Do not take a double dose to make up for a forgotten one. Taking two doses on the same day could increase the risk of side effects. If you have difficulty remembering to take your medication, consider setting a daily alarm or using a pill organizer to help you stay on track.
Overdose
If you accidentally take more sitagliptin than prescribed, contact your doctor or local poison control center immediately. In clinical trials, single doses of up to 800 mg were generally well tolerated. However, any overdose should be taken seriously and managed under medical supervision. Treatment is supportive, and sitagliptin is not efficiently removed by hemodialysis (only about 13.5% was removed over a 3–4 hour session in clinical studies).
Discontinuing sitagliptin abruptly can lead to a rise in blood sugar levels. If you wish to stop or change your diabetes medication, always discuss this with your healthcare provider first. They can help you transition safely and ensure your blood sugar remains well controlled.
What Are the Side Effects of Sitagliptin?
Common side effects of sitagliptin include headache, upper respiratory tract infection, stuffy or runny nose, and joint pain. When combined with other diabetes drugs, low blood sugar may occur. Rare but serious side effects include pancreatitis, severe allergic reactions, and bullous pemphigoid. Stop taking sitagliptin and seek immediate medical attention for severe abdominal pain or signs of a serious allergic reaction.
Like all medicines, sitagliptin can cause side effects, although not everyone experiences them. Most side effects are mild to moderate and typically resolve on their own. It is important to be aware of both common and serious side effects so you can take appropriate action if they occur.
- Severe and persistent abdominal pain that may radiate to the back, with or without nausea and vomiting – these could be signs of pancreatitis
- Severe allergic reaction: rash, hives, blisters, peeling skin, or swelling of the face, lips, tongue, or throat causing difficulty breathing or swallowing
Common Side Effects
May affect up to 1 in 10 people
- Low blood sugar (hypoglycemia) – especially when combined with sulfonylureas, insulin, or metformin
- Headache
- Upper respiratory tract infection
- Stuffy or runny nose and sore throat (nasopharyngitis)
- Osteoarthritis (joint inflammation)
- Pain in arms or legs
- Nausea (particularly when combined with metformin)
- Flatulence (gas)
- Constipation
- Swelling of hands or feet (peripheral edema) – when used with pioglitazone
Uncommon Side Effects
May affect up to 1 in 100 people
- Dizziness
- Constipation
- Itching (pruritus)
- Abdominal pain
- Diarrhea
- Drowsiness
- Dry mouth (when used with insulin)
Rare Side Effects
May affect up to 1 in 1,000 people
- Decreased platelet count (thrombocytopenia)
Not Known (frequency cannot be estimated)
Reported from post-marketing surveillance
- Severe allergic reactions (anaphylaxis, angioedema)
- Pancreatitis (inflammation of the pancreas)
- Kidney problems (sometimes requiring dialysis)
- Bullous pemphigoid (blistering skin condition)
- Interstitial lung disease
- Vomiting
- Joint pain (arthralgia)
- Muscle pain (myalgia)
- Back pain
- Rash, hives
Side Effects by Combination Therapy
The type and frequency of side effects can vary depending on which other diabetes medications you take alongside sitagliptin. When combined with metformin, gastrointestinal symptoms such as nausea, flatulence, and vomiting are more commonly reported. When combined with a sulfonylurea and metformin, hypoglycemia occurs more frequently and is classified as very common (affecting more than 1 in 10 people). When combined with insulin, flu-like symptoms and dry mouth have been reported. When combined with pioglitazone, peripheral edema (swelling of hands and feet) is more common.
Most side effects of sitagliptin are mild and transient. However, if any side effect becomes severe, persists, or causes you concern, consult your healthcare provider. Your doctor can help determine whether the side effect is related to sitagliptin or another medication, and may adjust your treatment accordingly.
Reporting Side Effects
Reporting suspected adverse reactions after a medicine has been authorized is important. It allows ongoing monitoring of the benefit-risk balance of the medicine. Healthcare professionals and patients can report side effects to their national drug regulatory authority, such as the FDA in the United States, the MHRA in the United Kingdom, or the EMA in Europe.
How Should You Store Sitagliptin?
Store sitagliptin tablets at room temperature, away from moisture and direct sunlight. Keep in the original blister pack until use. No special temperature requirements. Keep out of reach of children and do not use after the expiration date.
Proper storage of your medication is essential to maintain its effectiveness and safety throughout its shelf life. Follow these guidelines for storing sitagliptin:
- Temperature: No special storage temperature requirements. Store at room temperature, typically between 15°C and 30°C (59°F and 86°F).
- Moisture: Keep the tablets in their original blister packaging until you are ready to take them. This protects against moisture, which can degrade the medication.
- Light: Avoid exposing the tablets to direct sunlight or excessive heat.
- Children: Always store medications out of the sight and reach of children.
- Expiration date: Do not use sitagliptin after the expiration date printed on the blister pack and carton (marked as "EXP"). The expiration date refers to the last day of the indicated month.
Do not dispose of medications by flushing them down the toilet or throwing them in household waste. Ask your pharmacist about local medication take-back programs or proper disposal methods. These measures help protect the environment and prevent accidental exposure.
What Does Sitagliptin Contain?
Each sitagliptin film-coated tablet contains sitagliptin (as sitagliptin hydrochloride monohydrate) as the active ingredient, along with inactive ingredients including microcrystalline cellulose, calcium hydrogen phosphate, croscarmellose sodium, and magnesium stearate. The tablets are available in 25 mg, 50 mg, and 100 mg strengths.
Active Ingredient
The active substance in sitagliptin tablets is sitagliptin, present in the form of sitagliptin hydrochloride monohydrate. The three available strengths contain amounts of sitagliptin hydrochloride monohydrate equivalent to 25 mg, 50 mg, or 100 mg of sitagliptin, respectively. This is the compound responsible for the therapeutic blood-sugar-lowering effect.
Inactive Ingredients (Excipients)
The inactive ingredients help form the tablet and protect it:
- Tablet core: Microcrystalline cellulose (E460), calcium hydrogen phosphate, croscarmellose sodium (E468), and magnesium stearate (E470b)
- Film coating: Poly(vinyl alcohol), macrogol 3350, talc (E553b), titanium dioxide (E171), red iron oxide (E172), and yellow iron oxide (E172)
Sitagliptin tablets contain less than 1 mmol (23 mg) of sodium per tablet, meaning they are essentially sodium-free. This is relevant for patients on a sodium-restricted diet.
Tablet Appearance
- 25 mg: Pink, round, film-coated tablet with a flat edge, approximately 6–6.4 mm in diameter
- 50 mg: Light beige, round, film-coated tablet with a beveled edge, approximately 8–8.4 mm in diameter
- 100 mg: Beige, round, film-coated tablet with a beveled edge, approximately 10–10.4 mm in diameter
Tablets are supplied in opaque PVC/PE/PVDC-aluminum or OPA/aluminum/PVC/aluminum blister packs. Available pack sizes include 28, 30, 56, 98, and 100 film-coated tablets, though not all pack sizes may be marketed in all countries.
Frequently Asked Questions About Sitagliptin
Sitagliptin is a DPP-4 inhibitor used to treat type 2 diabetes mellitus in adults. It works by increasing insulin production after meals and reducing the amount of sugar produced by the body. It can be used alone when diet and exercise are insufficient, or in combination with other diabetes medications such as metformin, sulfonylureas, pioglitazone, or insulin. Sitagliptin is not used for type 1 diabetes or diabetic ketoacidosis.
Common side effects include headache, upper respiratory tract infection, stuffy or runny nose and sore throat, osteoarthritis, and pain in arms or legs. When combined with other diabetes medications, low blood sugar (hypoglycemia) is also common. Gastrointestinal symptoms like nausea, flatulence, and constipation may occur, particularly when used with metformin. Most side effects are mild and resolve on their own.
Cases of acute pancreatitis have been reported in patients taking sitagliptin during clinical trials and post-marketing surveillance. While a direct causal relationship has not been definitively established, you should stop taking sitagliptin and contact your doctor immediately if you experience severe, persistent abdominal pain that may radiate to the back, with or without nausea and vomiting. Risk factors include a history of pancreatitis, gallstones, alcohol dependence, and very high triglyceride levels.
Yes, sitagliptin and metformin are one of the most commonly prescribed combinations for type 2 diabetes. The two drugs work through complementary mechanisms: metformin reduces glucose production by the liver and improves insulin sensitivity, while sitagliptin enhances incretin hormones to boost insulin secretion after meals. This combination provides better blood sugar control than either drug alone. A fixed-dose combination tablet containing both sitagliptin and metformin is also available (marketed as Janumet).
Sitagliptin should not be used during pregnancy. There is insufficient data from human studies, and animal studies at high doses have shown some reproductive effects. If you are pregnant, planning a pregnancy, or discover you are pregnant while taking sitagliptin, contact your doctor immediately. Insulin is generally the preferred treatment for managing blood sugar during pregnancy. Sitagliptin should also not be used while breastfeeding, as it is not known whether it passes into breast milk.
Sitagliptin is considered weight-neutral, meaning it generally does not cause significant weight gain or weight loss. This is an advantage compared to some other diabetes medications like sulfonylureas, insulin, and thiazolidinediones, which can lead to weight gain. In clinical trials, sitagliptin was associated with minimal changes in body weight. If weight management is a priority in your diabetes treatment plan, discuss this with your doctor.
All information is based on international medical guidelines and peer-reviewed research: EMA Summary of Product Characteristics for sitagliptin, ADA Standards of Care in Diabetes 2025, NICE Guidelines for Type 2 Diabetes Management, the TECOS cardiovascular outcomes trial published in the New England Journal of Medicine, and WHO Model List of Essential Medicines. All medical claims follow evidence level 1A, the highest quality of evidence based on systematic reviews and randomized controlled trials.
References
- European Medicines Agency (EMA). Januvia (sitagliptin) – Summary of Product Characteristics. Last updated 2024. EMA – Januvia EPAR
- American Diabetes Association (ADA). Standards of Care in Diabetes – 2025. Diabetes Care. 2025;48(Supplement 1). ADA Standards of Care 2025
- Green JB, Bethel MA, Armstrong PW, et al. Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes (TECOS). N Engl J Med. 2015;373(3):232-242. doi:10.1056/NEJMoa1501352
- National Institute for Health and Care Excellence (NICE). Type 2 Diabetes in Adults: Management (NG28). Last updated 2024. NICE NG28
- World Health Organization (WHO). Model List of Essential Medicines – 23rd List. 2023. WHO Essential Medicines List
- U.S. Food and Drug Administration (FDA). Januvia (sitagliptin) Prescribing Information. FDA Prescribing Information
- Deacon CF. Dipeptidyl peptidase 4 inhibitors in the treatment of type 2 diabetes mellitus. Nature Reviews Endocrinology. 2020;16(11):642-653. doi:10.1038/s41574-020-0399-8
- Nauck MA, Meier JJ. The incretin effect in healthy individuals and those with type 2 diabetes: physiology, pathophysiology, and response to therapeutic interventions. Lancet Diabetes Endocrinol. 2016;4(6):525-536.
About Our Medical Editorial Team
This article was written and reviewed by the iMedic Medical Editorial Team, which includes board-certified physicians specializing in endocrinology, diabetology, and clinical pharmacology. Our editorial process ensures that all content meets the highest standards of medical accuracy, following the GRADE evidence framework and international clinical guidelines.
All drug information is verified against the European Medicines Agency (EMA) Summary of Product Characteristics, FDA prescribing information, and current clinical guidelines (ADA, NICE, WHO).
Evidence Level 1A – based on systematic reviews, meta-analyses of randomized controlled trials, and landmark cardiovascular outcomes trials (TECOS).
No pharmaceutical company sponsorship or advertising. All content is editorially independent with no commercial funding or conflicts of interest.
This article is reviewed and updated regularly to reflect the latest clinical evidence, regulatory changes, and guideline updates.